RE: The way market thinks18 Feb 2026 18:07
FY25 has just been restated, with revenue reduced from £4.64 million to £3.87 million and adjusted EBITDA from (0.41) million to (1.17) million after the removal of £0.77 million accrued royalty income. The Board reports that Dermatonics and Bio-Tech Solutions are trading in line with the current Board’s expectations for FY26, contracts with key partners remain sound, and the Board Investigation is confident in the quality of the management team, the future potential of products, and the underlying businesses. Yet for FY26 they provide no revised guidance, only noting that results for the year ended 30 June 2026 will be significantly below current market expectations. If the Board reports that operations are trading in line with expectations and expresses confidence in its management team, products, and businesses, why not provide updated numbers for FY26? The ongoing investigation cannot explain this gap . They are expressing operational confidence while withholding guidance, which makes the two statements logically inconsistent and represents a massive red flag.